ClinicalTrials.gg
Not yet recruitingNCT07767435Updated Aug 17, 2026

Second Trimester Abortion With Letrozole and Misoprostol Compared to Misoprostol Alone

A Phase 1/2 interventional study of · Misoprostol + letrozole and misoprostol alone in Abortion Induced Complicated and Abortion, sponsored by Sohag University. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Sohag University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Termination of Second trimester Abortion with Letrozole and Misoprostol Compared to Misoprostol Alone

Read the detailed description

An online randomization program will be used to generate a random list and each patients' code will be kept in an opaque sealed envelope. Patients will be randomly allocated with 1:1 allocation ratio into two equal groups in a parallel manner:

  • Group I (Letrozole + Misoprostol): Patients will receive letrozole 2.5 mg orally the dose of letrozole is 4 tab once/day for 3 consecutive days, followed by vaginal misoprostol.
  • Group II (Misoprostol alone (: Patients will receive vaginal misoprostol alone using the same dosage schedule without letrozole pretreatment.

This study will be open-label due to different drugs and route of administrations used.

02

Conditions studied

  • Abortion Induced Complicated
  • Abortion

Keywords

  • medical abortion
  • induced abortion
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,235 studies on the registry; 639 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Pregnant women aged 18-45 years.
  • Failed pregnancy.
  • Gestational age between 14 and 20weeks, confirmed by ultrasonography on the day of admission.
  • concentration >9 g/dL.
  • Closed cervix.
  • Absence of products of conception in the cervical canal.

    - Exclusion Criteria:

  • Previous attempt to terminate the current pregnancy.
  • Molar pregnancy (hydatidiform mole).
  • Pathological uterine lesions including uterine fibroids and congenital uterine malformations.
  • Cardiac disease.
  • Renal disease.
  • Hemorrhagic disorders.
  • (BMI) >35 kg/m².
  • Documented or allergy to letrozole, misoprostol, or any of the study medications.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group I (Letrozole + Misoprostol)

    Group I (Letrozole + Misoprostol): Patients will receive letrozole 2.5 mg orally the dose of letrozole is 4 tab once/day for 3 consecutive days, followed by vaginal misoprostol

    Drug: · Misoprostol + letrozole

  • Active comparator
    Group II (Misoprostol alone

    · Group II (Misoprostol alone (: Patients will receive vaginal misoprostol alone using the same dosage schedule without letrozole pretreatment.

    Drug: misoprostol alone

Interventions

  • Drug· Misoprostol + letrozole

    1. to compare the effect of letrozole plus misoprostol versus misoprostol alone for termination of second-trimester pregnancy. 2. to compare efficacy of letrozole and misoprostol versus misoprostol alone in theraputic abortion (living fetus) versus missed abortion.

  • DrugMisoprostolStudies of MisoprostolMisoprostol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. to compare the effect of letrozole plus misoprostol versus misoprostol alone for termination of second-trimester pregnancy. 2. to compare efficacy of letrozole and misoprostol versus misoprostol alone in theraputic abortion (living fetus) versus missed abortion

06

What researchers measure

Primary outcomes

  1. · Complete abortion rate.

    Time frame: 1 weak

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jan 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 17, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07767435
Lead sponsor
Sohag University
Responsible party
Ahmed Khalifa Ahmed Elsayed (Ahmed Khalifa Ahmed, Sohag University) — Principal investigator
First posted
Aug 17, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

ahmed khalifa elsayed, resident
Contact
AhmedKhalifa.ahmedelsayed@med.sohag.edu.eg
01142626766

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Misoprostol

Start the discussion